On February 10, 2026 Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence to accelerate oncology drug discovery and development, reported that CEO and President Panna Sharma will present at the 7th Glioblastoma Drug Development Summit, February 17–19, 2026, in Boston, MA.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
More information about the summit is available at: https://glioblastoma-drugdevelopment.com.
Lantern’s proprietary AI and machine learning platform, RADR, powered the development of LP-184 / STAR-001, a novel brain-penetrant therapeutic candidate. This work has driven the creation of Lantern’s wholly owned subsidiary, Starlight Therapeutics, which is advancing clinical development for multiple CNS cancers, including recurrent glioblastoma and pediatric brain tumors such as atypical teratoid/rhabdoid tumors (ATRT)—for which STAR-001 has received both FDA Orphan Drug Designation and Rare Pediatric Disease Designation.
In his presentation on Day Two (Thursday, February 19, 2026, at 10:30 a.m. ET), Mr. Sharma will highlight how Lantern applied RADR to:
Elucidate the mechanism of action of STAR-001
Identify patient biomarkers to inform clinical use
Select optimal cancer indications
Discover novel combination therapies in neuro-oncology
The talk will emphasize AI-driven insights and approaches that are helping overcome challenges in treating aggressive brain cancers like glioblastoma and ATRT.
(Press release, Lantern Pharma, FEB 10, 2026, View Source [SID1234662576])